ArticleBlood cancer journal2013
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups.
Article in Blood cancer journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Discrepancies in the Detection ofDiseases (Basel, Switzerland) · 2026Article
- Function of PML-RARA in Acute Promyelocytic Leukemia.Advances in experimental medicine and biology · 2024Review
- Review
- The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.Leukemia · 2019Article
- Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.Blood · 2018Article
- PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.Leukemia · 2017Article
- Molecular Profiling: A Case ofCase reports in hematology · 2017Article
- Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.Leukemia · 2016Article
- The Mutational Landscape of Acute Promyelocytic Leukemia Reveals an Interacting Network of Co-Occurrences and Recurrent Mutations.PloS one · 2016Article
- Review
- c.9253-6T>c REV3L: A novel marker of poor prognosis in Myelodysplastic syndrome.Hematology, transfusion and cell therapyArticle
Corrections and comments
- Erratum issued
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.